SCHEMBL17940

SCHEMBL17940

Cn1nc(C(N)=O)cc1C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.49
PLA2G10 O15496 3/20 0.44
ALDH1A1 P00352 3/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.42
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SCN9A Q15858 4/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CFTR P13569 1/20 0.38
HTT P42858 1/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27787731 0.85 PKM (0.51) PKMALDH1A1NPC1RAB9AKDM4E
SCHEMBL23252286 0.84 PLA2G10 (0.45) PLA2G10ALDH1A1KDM4ESCN9AL3MBTL1
SCHEMBL18510 0.84 PKM (0.54) PKMALDH1A1NPC1RAB9AKDM4E
SCHEMBL16690902 0.84 PKM (0.50) PKMALDH1A1NPC1RAB9AKDM4E
SCHEMBL24571057 0.82 PKM (0.49) PKMALDH1A1NPC1RAB9AKDM4E
SCHEMBL28057286 0.81 PKM (0.49) PKMALDH1A1NPC1RAB9AKDM4E
SCHEMBL15101576 0.80 PLA2G10 (0.38) PKMPLA2G10ALDH1A1NPC1RAB9A
SCHEMBL18120300 0.79 PKM (0.47) PKMALDH1A1NPC1RAB9AKDM4E
SCHEMBL19196 0.79 PKM (0.43) PKMALDH1A1NPC1RAB9AMAPT
SCHEMBL31459702 0.79 ALDH1A1 (0.50) PKMALDH1A1NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376478-B1 PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE NOVARTIS AG (CH) 2017-04-19 EP claimed
US-12583851-B2 Heteroaryl-substituted pyrazine derivatives as pesticides ELANCO ANIMAL HEALTH GMBH (DE) 2026-03-24 US disclosed
CN-112204009-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2024-05-07 CN disclosed
US-20230023326-A1 HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES ELANCO ANIMAL HEALTH GMBH (DE) 2023-01-26 US disclosed
US-20230023326-A1 HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES ELANCO ANIMAL HEALTH GMBH (DE) 2023-01-26 US disclosed
WO-2022136844-A1 N-(PYRIDIN-2-YL)-6,7,8,9-TETRAHYDRO-5H-5,8-EPIMINOCYCLOHEPTA[C]PYRIDINE-10-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS GPR65 MODULATORS FOR THE TREATMENT OF CANCER Pathios Therapeutics Limited (GB) 2022-06-30 WO disclosed
EP-3904349-A2 N-(CYCLOPROPYLMETHYL)-5-(METHYLSULFONYL)-N-{1-[1-(PYRIMIDIN-2-YL)-1H-1,2,4-TRIAZOL-5-YL]ETHYL}HETEROCYCLYL AMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS PESTICIDES Bayer Aktiengesellschaft (DE) 2021-11-03 EP disclosed
WO-2021069575-A1 HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES BAYER ANIMAL HEALTH GMBH (DE) 2021-04-15 WO disclosed
EP-2376478-B1 PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE NOVARTIS AG (CH) 2017-04-19 EP disclosed
EP-2632458-B1 DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE NOVARTIS AG (CH) 2015-08-12 EP disclosed
US-20130012529-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2013-01-10 US disclosed
US-20130005751-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2013-01-03 US disclosed
US-20130005750-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2013-01-03 US disclosed
US-20130005753-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2013-01-03 US disclosed
US-20120245187-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2012-09-27 US disclosed
US-8242125-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2012-08-14 US disclosed
WO-2012025460-A1 OXADIAZOLINONE DERIVATIVES AND USE THEREOF IN PEST CONTROL BAYER CROPSCIENCE AG (DE) 2012-03-01 WO disclosed
EP-2376478-A2 PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE Novartis AG (CH) 2011-10-19 EP disclosed
US-20100168082-A1 Heterobicyclic Carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2010-07-01 US disclosed
WO-2010066684-A2 Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease NOVARTIS AG (CH) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583851-B2 Heteroaryl-substituted pyrazine derivatives as pesticides CBR3, CYCS, CWC15 PKM 3610/4885PLA2G10 3624/4885ALDH1A1 2552/4885
US-20130005753-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES CDK2, PHKG1, PHKG2 PKM 443/4885PLA2G10 3818/4885ALDH1A1 3736/4885
US-20230023326-A1 HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES DDT, PRXL2A, CAT PKM 1516/4885PLA2G10 2472/4885ALDH1A1 3500/4885
US-20120245187-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES CDK2, PHKG1, PHKG2 PKM 443/4885PLA2G10 3818/4885ALDH1A1 3736/4885
US-20130005751-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES CDK2, PHKG1, PHKG2 PKM 443/4885PLA2G10 3818/4885ALDH1A1 3736/4885
US-20130005750-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES CDK2, PHKG1, PHKG2 PKM 443/4885PLA2G10 3818/4885ALDH1A1 3736/4885
US-20100168082-A1 Heterobicyclic Carboxamides as inhibitors for kinases CDK2, PHKG1, PHKG2 PKM 443/4885PLA2G10 3818/4885ALDH1A1 3736/4885
US-20130012529-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES CDK2, PHKG1, PHKG2 PKM 443/4885PLA2G10 3818/4885ALDH1A1 3736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.